Tadalafil in Hepatic Impairment: PK and Labeling Context

Tadalafil Hepatic-Impairment Context at a Glance

Current labeling does not use one universal rule for every tadalafil product. The relevant interpretation depends on hepatic severity, whether tadalafil is used as needed or once daily, and whether the product is labeled for ED/BPH or pulmonary arterial hypertension.

Mild and moderate hepatic impairment are generally represented as Child-Pugh Class A and B, while severe hepatic impairment is Child-Pugh Class C. The table below summarizes current U.S. label wording as a comparative regulatory framework rather than as an individualized prescribing tool.

The wording also differs in strength: CIALIS uses caution or not-recommended language, whereas PAH products such as ADCIRCA and TADLIQ use consider-starting and avoid-use language.

Why Liver Function Matters for Tadalafil

Tadalafil undergoes extensive hepatic metabolism before its metabolites are eliminated. Current CIALIS pharmacokinetics identifies CYP3A4 as the predominant metabolic pathway.

That makes liver function relevant even though a controlled 10 mg study did not show higher average AUC in subjects with mild or moderate hepatic impairment. Hepatic impairment affects more than a single exposure number: the evidence base becomes more limited at higher doses, with repeated dosing and with severe liver disease.

The detailed enzyme pathway itself belongs on the tadalafil metabolism page.

How Tadalafil Is Metabolized

Current CIALIS labeling states that tadalafil is predominantly metabolized by CYP3A4 to a catechol metabolite. That metabolite then undergoes extensive methylation and glucuronidation to form methylcatechol and methylcatechol glucuronide conjugates.

The major circulating metabolite is methylcatechol glucuronide, while current in-vitro data indicate that tadalafil metabolites are not expected to be pharmacologically active at observed concentrations. This metabolic sequence explains why hepatic function and CYP3A-related drug interactions are pharmacologically relevant, even though they are not identical clinical problems.

The present page keeps the pathway at a high level so it does not duplicate the dedicated metabolism and CYP3A4 interaction pages.

Current Tadalafil Labels Use Child-Pugh Severity Categories

Current tadalafil labels organize hepatic impairment around Child-Pugh classes. Class A corresponds to the mild category used in the labels, Class B to moderate impairment and Class C to severe impairment.

These categories should not be replaced by a generic statement that someone has 'liver disease.' Different liver conditions and laboratory abnormalities do not automatically translate into the same tadalafil label category without clinical assessment.

This page therefore uses the Child-Pugh terminology found in current prescribing information rather than offering a self-assessment tool for liver severity.

What the Hepatic Pharmacokinetic Study Actually Showed

In current CIALIS clinical pharmacology, tadalafil exposure measured by AUC in subjects with mild or moderate hepatic impairment was comparable to exposure in healthy subjects after administration of a 10 mg dose. This is an important contrast with renal impairment, where current labeling documents clear increases in tadalafil AUC.

The hepatic study does not establish equivalent pharmacokinetics at every tadalafil dose or regimen. Current labeling specifically states that there are no available data for doses higher than 10 mg in patients with hepatic impairment and that data are insufficient in Child-Pugh Class C.

For a deeper explanation of what AUC represents, see the tadalafil AUC page.

Comparable AUC Does Not Mean Unrestricted Use

A common interpretation error is to read 'comparable AUC' and conclude that hepatic impairment does not matter for tadalafil. The current labels do not support that conclusion because the PK comparison was limited to a 10 mg dose in Child-Pugh A or B subjects.

The evidence does not establish the same result at higher tadalafil doses, after chronic daily administration or in severe hepatic impairment. Current labeling therefore remains cautious even though the available single-dose AUC finding in mild or moderate impairment was not elevated.

This distinction prevents a limited pharmacokinetic result from being generalized beyond the population and dose that were actually studied.

CIALIS as Needed: Mild or Moderate Hepatic Impairment

For as-needed use in Child-Pugh Class A or B hepatic impairment, current CIALIS labeling states that the dose should not exceed 10 mg once per day. It also advises caution because use of CIALIS once per day has not been extensively evaluated in patients with hepatic impairment.

This label statement should be read as a ceiling within a prescribing framework, not as a recommendation that every patient with mild or moderate hepatic impairment should receive 10 mg. Other clinical factors, interactions and the reason tadalafil is being used still matter.

The general intermittent-treatment framework belongs on the as-needed tadalafil page.

Once-Daily CIALIS Uses a Different Hepatic Framework

Current CIALIS labeling does not provide a simple hepatic dose reduction table for once-daily treatment. Instead, it states that once-daily CIALIS has not been extensively evaluated in patients with mild or moderate hepatic impairment and that caution is advised if it is prescribed.

For severe hepatic impairment, once-daily use is not recommended. The absence of a specific reduced daily milligram value is itself part of the label and should not be filled with an invented adjustment.

The continuous-exposure treatment model is explained separately on the daily tadalafil page.

BPH and ED/BPH Use the Once-Daily Hepatic Framework

CIALIS treatment for BPH and for combined ED/BPH is based on once-daily administration, so the once-daily hepatic warning is the relevant framework rather than the as-needed ED ceiling. Current labeling does not create a separate liver-specific BPH dose table.

For mild or moderate hepatic impairment, the key label language remains that once-daily use has not been extensively evaluated and caution is advised. For severe hepatic impairment, use is not recommended.

The therapeutic role of tadalafil in urinary symptoms belongs on the tadalafil for BPH page and the combined ED/BPH page.

Why As-Needed and Once-Daily Hepatic Instructions Are Not Interchangeable

Current CIALIS labeling provides an explicit 10 mg ceiling for as-needed use in mild or moderate hepatic impairment, but it does not provide an equivalent numeric hepatic adjustment for once-daily use. Instead, daily therapy is described as insufficiently evaluated and requiring caution.

That difference reflects the available evidence base rather than proof that one regimen is universally safer than the other. Intermittent and repeated dosing create different exposure patterns, and current labeling preserves that distinction.

A hepatic page therefore should not copy the as-needed 10 mg limit into the once-daily regimen.

ADCIRCA for PAH Has a Separate Hepatic-Impairment Framework

ADCIRCA is tadalafil labeled for pulmonary arterial hypertension, so its hepatic instructions should remain separate from CIALIS ED/BPH guidance. For mild or moderate hepatic cirrhosis, Child-Pugh Class A or B, current ADCIRCA labeling states that because clinical experience is limited, a starting dose of 20 mg once daily should be considered.

Patients with severe hepatic cirrhosis, Child-Pugh Class C, were not studied in the relevant label framework, and ADCIRCA should be avoided. This differs in wording and dose context from CIALIS, even though the active drug is tadalafil.

The PAH indication itself is covered on the tadalafil for pulmonary arterial hypertension page, while product-specific details belong on the Adcirca page.

TADLIQ Uses the PAH Hepatic Framework in an Oral Suspension

TADLIQ is tadalafil oral suspension labeled for pulmonary arterial hypertension. Its current hepatic instructions mirror the PAH tablet approach while expressing the dose in both milligrams and milliliters.

For Child-Pugh A or B hepatic impairment, current TADLIQ labeling says to consider a starting dose of 20 mg, or 5 mL, once daily because clinical experience in mild to moderate hepatic cirrhosis is limited. For Child-Pugh C, the label says to avoid use.

The formulation and product identity are covered separately on the TADLIQ page.

ED/BPH and PAH Hepatic Instructions Should Not Be Mixed

CIALIS, ADCIRCA and TADLIQ contain tadalafil but use different indication-specific treatment frameworks. A PAH starting dose should not be inserted into an ED/BPH answer, and the CIALIS as-needed 10 mg ceiling should not be applied to a PAH product.

The pharmacokinetic hepatic study is shared across the tadalafil evidence base, but regulatory instructions still differ by product and regimen. Product identity therefore remains important even when the active ingredient is identical.

This distinction is especially relevant when a medication list shows only 'tadalafil' without stating why the drug is being used.

Severe Hepatic Impairment Is Primarily an Evidence-Gap Problem in Current Labeling

Current tadalafil pharmacokinetic sections state that insufficient data are available for subjects with severe hepatic impairment, Child-Pugh Class C. The labels therefore do not provide a well-characterized exposure estimate or an evidence-based adjustment formula for that population.

CIALIS describes use in severe hepatic impairment as not recommended, while ADCIRCA and TADLIQ say to avoid use. Those terms should be preserved rather than replaced with a made-up lower dose based on extrapolation from Child-Pugh A or B data.

The absence of adequate evidence is itself clinically meaningful and should not be disguised as a precise pharmacokinetic prediction.

Hepatic Impairment and CYP3A4 Drug Interactions Are Related but Not the Same

Tadalafil is predominantly metabolized by CYP3A4, but liver impairment should not be treated as if it were simply another CYP3A4 inhibitor. Hepatic disease is an organ-function context, whereas ketoconazole, ritonavir and other CYP3A modifiers alter enzyme activity through drug interactions.

The two issues can both influence how tadalafil is evaluated clinically, but current labeling provides separate sections and separate evidence for them. It would be inaccurate to apply the quantitative AUC increase from a potent CYP3A4 inhibitor to a patient merely because hepatic impairment is present.

Enzyme-specific interaction data belong on the tadalafil and CYP3A4 page.

Liver Disease Does Not Remove the Need for a Separate Drug-Interaction Review

A hepatic-impairment assessment and a medication-interaction assessment answer different questions. A patient may have Child-Pugh A or B hepatic impairment and also be taking a CYP3A4 inhibitor, inducer, nitrate, alpha-blocker or antihypertensive medicine that has its own tadalafil implications.

Current labeling should therefore not be compressed into one rule such as 'liver disease means use a lower dose.' Product, regimen, hepatic severity and interacting drugs remain separate pieces of the overall safety assessment.

The broader medication-interaction framework is covered on the tadalafil drug-interactions page.

Why Label Restrictions Are Broader Than the Available 10 mg AUC Result

The measured hepatic PK result answers a narrow question: average tadalafil AUC after a 10 mg dose in Child-Pugh A or B subjects was comparable to healthy controls. It does not answer every question about repeated exposure, tolerability, higher-dose PAH treatment or severe cirrhosis.

Regulatory labeling therefore combines pharmacokinetic data with the amount of clinical experience available in each treatment setting. This is why an apparently reassuring AUC result can coexist with caution, dose ceilings or avoid-use language.

The broader concept of systemic exposure is explained on the tadalafil exposure page.

Hepatic Impairment Is Not a Blanket Formal Tadalafil Contraindication

Current tadalafil labels do not classify all hepatic impairment as a formal contraindication. Mild and moderate hepatic impairment remain within label-defined caution or modified-use frameworks, while severe impairment is handled with not-recommended or avoid-use wording depending on the product.

That regulatory distinction matters. 'Contraindicated,' 'not recommended,' 'avoid use' and 'use with caution' are not interchangeable terms and should not be collapsed into a generic statement that tadalafil is prohibited in liver disease.

The formal contraindication list is covered on the tadalafil contraindications page.

Hepatic Impairment Is Different From Asking Whether Tadalafil Causes Liver Injury

This page addresses how pre-existing hepatic impairment affects tadalafil use and evidence interpretation. That is different from asking whether tadalafil itself causes a new liver injury or whether an abnormal liver test is attributable to treatment.

Keeping those questions separate improves both medical clarity and search intent. The presence of hepatic impairment does not by itself identify the cause of the underlying liver condition.

The relevant issue here is how established hepatic dysfunction intersects with tadalafil metabolism, available PK evidence and current product labeling.

Hepatic and Renal Impairment Do Not Produce the Same PK Pattern

The tadalafil evidence base shows why organ impairment should not be discussed generically. Renal impairment can substantially increase tadalafil AUC, whereas the available 10 mg hepatic study found comparable AUC in Child-Pugh A or B subjects and healthy controls.

The resulting labels also differ in their logic: renal restrictions are supported by measured exposure increases across renal categories, while hepatic restrictions rely heavily on limited experience, absent higher-dose data and inadequate evidence in severe impairment.

Renal-specific evidence belongs on the tadalafil renal impairment page.

Hepatic Impairment Is One Specific PK-Variability Context

Liver function is one potential determinant of tadalafil disposition, but this page is intentionally narrower than a general PK variability discussion. It owns Child-Pugh severity, hepatic PK findings and product-specific label consequences.

Other factors such as renal function, CYP3A modifiers, age, repeated dosing and PAH population pharmacokinetics belong in their own contexts. Keeping those mechanisms separate prevents the hepatic page from becoming a duplicate of a general exposure hub.

The integrative framework belongs on the tadalafil PK variability page.

Product Identification Matters Before Interpreting Hepatic Labeling

Tadalafil may appear as CIALIS, ADCIRCA, TADLIQ or a generic tadalafil product. The active ingredient is shared, but the indication and product label determine which hepatic framework applies.

A clinician reviewing a medication list therefore needs more context than the word 'tadalafil.' ED/BPH treatment and PAH treatment use different dosing frameworks even though their hepatic PK evidence is related.

Keeping product identity attached to indication prevents an ADCIRCA or TADLIQ starting framework from being copied into a CIALIS answer.

Tadalafil Hepatic-Context Checklist

A useful hepatic review begins with severity, product and regimen rather than jumping directly to a milligram value. It also keeps organ impairment separate from drug interactions that independently affect CYP3A metabolism.

The checklist below is designed to organize label interpretation, not to determine an individualized tadalafil dose.

Key Takeaways About Tadalafil and Hepatic Impairment

Tadalafil is metabolized predominantly by CYP3A4 in the liver, making hepatic function relevant to treatment interpretation. However, current clinical pharmacology found that tadalafil AUC after a studied 10 mg dose in Child-Pugh A or B impairment was comparable to exposure in healthy subjects.

That finding does not establish unrestricted use. Data above 10 mg are unavailable in hepatic impairment, once-daily CIALIS has not been extensively evaluated in mild or moderate impairment, PAH clinical experience is limited and severe Child-Pugh C impairment lacks adequate study data.

Current labeling therefore must be interpreted by product and regimen: CIALIS as needed has a 10 mg ceiling in Child-Pugh A/B, once-daily CIALIS uses a caution framework, and ADCIRCA or TADLIQ use PAH-specific consider-starting guidance in A/B while severe impairment is avoided.